Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy.

Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, Chin D, Capen A, Li Y, Meyer CM, Jones BD, Huang X, Luo S, Carpenito C, Roth KD, Nikolayev A, Tan B, Brahmachary M, Chodavarapu K, Dorsey FC, Manro JR, Doman TN, Donoho GP, Surguladze D, Hall G, Kalos M, Novosiadly R.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0433.2019. doi: 10.1158/1078-0432.CCR-19-0433. [Epub ahead of print]

PMID:
31409612
2.

Evaluation of quality of life in patients after cochlear implantation surgery in 2014-2017.

Czerniejewska-Wolska H, Kałos M, Gawłowska M, Sekula A, Mickiewicz P, Wiskirska-Woźnica B, Karlik M.

Otolaryngol Pol. 2019 Feb 28;73(2):11-17. doi: 10.5604/01.3001.0013.0400.

3.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6.

4.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE.

J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4.

5.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

6.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. Erratum in: J Immunother Cancer. 2018 Jun 4;6(1):45.

7.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.

Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.

8.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

9.

CART Targeting of Solid Tumors: More Pieces to the Puzzle.

Kalos M.

Clin Cancer Res. 2018 Mar 15;24(6):1246-1247. doi: 10.1158/1078-0432.CCR-17-3432. Epub 2018 Jan 18.

10.

High-content molecular profiling of T-cell therapy in oncology.

Novosiadly R, Kalos M.

Mol Ther Oncolytics. 2016 Mar 30;3:16009. doi: 10.1038/mto.2016.9. eCollection 2016. Review.

11.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

12.

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.

Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, June CH, Zhao Y.

Blood Cancer J. 2016 Jun 3;6(6):e430. doi: 10.1038/bcj.2016.38.

13.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

14.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

15.

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA.

Oncoimmunology. 2015 Aug 12;5(1):e1040216. eCollection 2016.

16.

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds.

Kalos M.

J Immunother Cancer. 2016 Feb 16;4:5. doi: 10.1186/s40425-016-0108-2. eCollection 2016.

17.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

18.

Quality of life and hearing after cochlear implant placement in patients over 60 years of age.

Czerniejewska-Wolska H, Kałos M, Sekula A, Piszczatowski B, Rutkowska J, Rogowski M, Zadrożniak M, Szymański M, Klatka J, Durko M, Pietruszewska W, Gawłowska MB, Kuśmierczyk J, Kruk-Krzemień A, Wiskirska-Woźnica B.

Otolaryngol Pol. 2015;69(4):34-9. doi: 10.5604/00306657.1163575.

PMID:
26388358
19.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

20.

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ.

Breast Cancer Res. 2015 Jun 28;17:89. doi: 10.1186/s13058-015-0599-7.

21.

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.

Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, Kirsch I, Gastier-Foster JM, Borowitz M, Desmarais C, Williamson D, Kalos M, Grupp SA.

Blood. 2015 May 28;125(22):3501-8. doi: 10.1182/blood-2014-12-615757. Epub 2015 Apr 10.

22.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

23.

Sign problem of the fermionic shadow wave function.

Calcavecchia F, Pederiva F, Kalos MH, Kühne TD.

Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Nov;90(5-1):053304. Epub 2014 Nov 4.

PMID:
25493901
24.

Chimeric antigen receptor T-cell therapy to target hematologic malignancies.

Kenderian SS, Ruella M, Gill S, Kalos M.

Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4.

25.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.

Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

26.

Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.

Lynch HE, Sanchez AM, D'Souza MP, Rountree W, Denny TN, Kalos M, Sempowski GD.

J Immunol Methods. 2014 Jul;409:62-71. doi: 10.1016/j.jim.2014.04.011. Epub 2014 May 4. Review.

27.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.

28.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH.

N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662.

29.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

30.

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.

Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. Erratum in: Cancer Immunol Res. 2015 Feb;3(2):217.

31.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

32.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1:26-31.

33.

Adoptive immunotherapy for cancer or viruses.

Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH.

Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9. Review.

34.

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, Jiang S, Medvec A, Danet-Desnoyers G, Watt C, Tomczak E, Kalos M, Riley JL, Wasik MA.

Am J Pathol. 2013 Dec;183(6):1971-80.

35.

Microsphere-based multiplex analysis of DNA methylation in acute myeloid leukemia.

Wertheim GB, Smith C, Figueroa ME, Kalos M, Bagg A, Carroll M, Master SR.

J Mol Diagn. 2014 Mar;16(2):207-15. doi: 10.1016/j.jmoldx.2013.10.010. Epub 2013 Dec 25.

36.

Adoptive immunotherapy for cancer.

Ruella M, Kalos M.

Immunol Rev. 2014 Jan;257(1):14-38. doi: 10.1111/imr.12136. Review.

PMID:
24329787
37.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.

38.

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

Kalos M, June CH.

Immunity. 2013 Jul 25;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002. Review.

39.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

40.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH.

Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.

41.

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA.

Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.

42.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH.

N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

43.

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.

Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1009-20. doi: 10.1158/1078-0432.CCR-12-2982.

44.

Biomarkers in T-cell therapy clinical trials.

Lacey SF, Kalos M.

Cytotherapy. 2013 Jun;15(6):632-40. doi: 10.1016/j.jcyt.2013.01.002. Epub 2013 Feb 14. Review.

PMID:
23415917
45.

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH.

Blood. 2013 Feb 28;121(9):1524-33. doi: 10.1182/blood-2012-07-447250. Epub 2012 Dec 20. Erratum in: Blood. 2014 Jul 24;124(4):663.

46.

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK.

Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22.

47.

T cell-based gene therapy of cancer.

Gill S, Kalos M.

Transl Res. 2013 Apr;161(4):365-79. doi: 10.1016/j.trsl.2012.11.002. Epub 2012 Dec 11. Review.

PMID:
23246626
48.

Conference scene: Immune signatures in the tumor and beyond.

Kandalaft LE, Kalos M, Melief CJ, Speiser DE, Coukos G.

Immunotherapy. 2012 Aug;4(8):761-72. doi: 10.2217/imt.12.70.

49.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

50.

Monoclonal TCR-redirected tumor cell killing.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK.

Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764.

PMID:
22561687

Supplemental Content

Support Center